MET and non-small cell lung carcinoma: Considering NSCLC, at the time of diagnosis, all advanced non-squamous NSCLC should be screened for EGFR (exon 18: G719x; exon 19: ex19del; exon 20: T790M, S768I, ex20ins; exon 21: L858R, L861Q), KRAS (G12C), BRAF (V600E), and HER2 mutations, for MET exon 14 skipping, and for ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 rearrangements [4].